x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The IMID Forum

The Immune-Mediated Inflammatory Disease Forum

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

education

All Episodes

00:28:57

Author Interview: Doctor Rodrigo Garcia‑Salinas,...

The IMID Forum ·

2025/08/28

Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.

en

00:45:23

Author Interview: Doctor Martin Schaefer and...

The IMID Forum ·

2025/08/14

Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the rheumatoid research centre in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.

en

00:17:45

Discussing PsA: Post hoc analyses on secukinumab and...

The IMID Forum ·

2025/08/07

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.

en

00:13:24

Discussing RA: Comparative outcomes of JAK inhibition...

The IMID Forum ·

2025/07/31

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’

en

00:16:44

Discussing axSpA: Secukinumab treatment outcomes on...

The IMID Forum ·

2025/07/10

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.

en

00:41:27

Difficult-to-treat disease in Rheumatology Podcast...

The IMID Forum ·

2025/07/03

Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.

en

01:05:19

EULAR 2025 Review Podcast

The IMID Forum ·

2025/07/02

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they review their highlights of the recent EULAR 2025 congress, and watch them discuss the key abstracts and information.

en

00:15:20

Discussing RA: Impact of TOF on BMI, UPA monotherapy...

The IMID Forum ·

2025/06/26

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-inadequate response, and the treatment of JAKis versus TNFis in RA.

en

00:03:25

EULAR 2025 Highlights: Day 4

The IMID Forum ·

2025/06/14

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).

en

00:02:36

EULAR 2025 Highlights: Day 3

The IMID Forum ·

2025/06/13

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).

en

00:23:11

Discussing PsA: Real-world data on biologic switching...

The IMID Forum ·

2025/06/12

Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.

en

00:04:39

EULAR 2025 Highlights: Day 2

The IMID Forum ·

2025/06/12

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).

en

00:04:03

EULAR 2025 Day 1 Daily Highlights

The IMID Forum ·

2025/06/11

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 1 of EULAR 2025 (Wednesday, June 11).

en

00:25:23

EULAR 2025 Preview Podcast

The IMID Forum ·

2025/06/09

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.

en

00:10:25

Discussing RA: MACE in RA, data from the "JAK-pot"...

The IMID Forum ·

2025/06/05

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.

en

00:30:26

Podcast: AuToDeCRA, June 2025

The IMID Forum ·

2025/06/04

Join Professor Ian McInnes from the University of Glasgow, and Professors John Isaacs and Andrew Cope, as they discuss the latest AuToDeCRA study and what this means for rheumatology.

en

00:23:13

Webinar Highlights Podcast: Advancing Patient Care...

The IMID Forum ·

2025/05/28

Join Professor Herve Bachelez and Professors Iain McInnes and Tim Orchard as they discuss the recent webinar hosted on the IMID Forum: “Advancing Patient Care Through an Interdisciplinary Approach to IMIDs”. Watch them discuss key highlights from the webinar including the clinical pathogenetic pathways, the Rheum-Derm-Gastro triggers and its implications, and interdisciplinary management in IBD and psoriasis.

en

00:26:08

Author Interview: Dr Saqr Alsakarneh, May 2025

The IMID Forum ·

2025/05/22

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Saqr Alsakarneh, Internal Medicine Resident at University of Missouri–Kansas City in the US, as they discuss ‘Risk of De Novo Inflammatory Bowel Disease in Patients with Psoriasis and Psoriatic Arthritis Treated with IL-17A Inhibitors: A Population-Based Study’.

en

00:32:17

Discussing axSpA: JAKi cycling and long-term safety...

The IMID Forum ·

2025/05/08

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cycling with other TNF inhibitors, and the second investigates long-term safety of bimekizumab in adult patients with axSpA or PsA.

en

00:08:31

Discussing RA: MACE, VTE, and malignancy in...

The IMID Forum ·

2025/05/01

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

en

387 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College